305 related articles for article (PubMed ID: 24695356)
1. Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry.
Gous T; Couchman L; Patel JP; Paradzai C; Arya R; Flanagan RJ
Ther Drug Monit; 2014 Oct; 36(5):597-605. PubMed ID: 24695356
[TBL] [Abstract][Full Text] [Related]
2. Paramagnetic micro-particles as a tool for rapid quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma by UHPLC-MS/MS.
Wiesen MHJ; Blaich C; Streichert T; Michels G; Müller C
Clin Chem Lab Med; 2017 Aug; 55(9):1349-1359. PubMed ID: 28328524
[TBL] [Abstract][Full Text] [Related]
3. Quantification of Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Serum by UHPLC-MS/MS-Method Development, Validation, and Application.
Lindahl S; Dyrkorn R; Spigset O; Hegstad S
Ther Drug Monit; 2018 Jun; 40(3):369-376. PubMed ID: 29578938
[TBL] [Abstract][Full Text] [Related]
4. Measurement of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma using automated online solid-phase extraction combined with ultra-performance liquid chromatography-tandem mass spectrometry and its comparison with coagulation assays.
Kuhn J; Gripp T; Flieder T; Hammerschmidt A; Hendig D; Faust I; Knabbe C; Birschmann I
Clin Chim Acta; 2018 Nov; 486():347-356. PubMed ID: 30114406
[No Abstract] [Full Text] [Related]
5. Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants.
Schmitz EM; Boonen K; van den Heuvel DJ; van Dongen JL; Schellings MW; Emmen JM; van der Graaf F; Brunsveld L; van de Kerkhof D
J Thromb Haemost; 2014 Oct; 12(10):1636-46. PubMed ID: 25142183
[TBL] [Abstract][Full Text] [Related]
6. A simple and fast HPLC-MS/MS method for simultaneous determination of direct oral anticoagulants apixaban, dabigatran, rivaroxaban in human plasma.
Lagoutte-Renosi J; Le Poupon J; Girard A; Montange D; Davani S
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Nov; 1100-1101():43-49. PubMed ID: 30292948
[TBL] [Abstract][Full Text] [Related]
7. Direct oral anticoagulants--pharmacology, drug interactions, and side effects.
Dempfle CE
Semin Hematol; 2014 Apr; 51(2):89-97. PubMed ID: 24861792
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the in vitro stability of direct oral anticoagulants in blood samples under different storage conditions.
Thuile K; Giacomuzzi K; Jani E; Marschang P; Mueller T
Scand J Clin Lab Invest; 2021 Oct; 81(6):461-468. PubMed ID: 34278897
[TBL] [Abstract][Full Text] [Related]
9. A UHPLC-MS/MS method to simultaneously quantify apixaban, edoxaban and rivaroxaban in human plasma and breast milk: For emerging lactation studies.
Zhao Y; Couchman L; Kipper K; Arya R; Patel JP
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 May; 1144():122095. PubMed ID: 32251991
[TBL] [Abstract][Full Text] [Related]
10. Quantitation of the Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Warfarin in Plasma Using Ultra-Performance Liquid Chromatography with Tandem Mass Spectrometry (UPLC-MS/MS).
Noguez JH; Ritchie JC
Methods Mol Biol; 2016; 1383():21-7. PubMed ID: 26660170
[TBL] [Abstract][Full Text] [Related]
11. Development, validation and application of a new HPLC-DAD method for simultaneous quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma.
Gouveia F; Bicker J; Santos J; Rocha M; Alves G; Falcão A; Fortuna A
J Pharm Biomed Anal; 2020 Mar; 181():113109. PubMed ID: 31981828
[TBL] [Abstract][Full Text] [Related]
12. Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method.
Zhang WL; Lou D; Zhang DT; Zhang Y; Huang HJ
J Thromb Thrombolysis; 2016 Aug; 42(2):205-11. PubMed ID: 27116356
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
Gosselin R; Grant RP; Adcock DM
Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous Determination of Dabigatran, Rivaroxaban, and Apixaban in Human Plasma by Liquid Chromatography/Tandem Mass Spectrometry.
Zhang M; Moore GA; Chin PKL
Ther Drug Monit; 2020 Jun; 42(3):473-480. PubMed ID: 32053549
[TBL] [Abstract][Full Text] [Related]
15. New oral anticoagulants for the treatment of venous thromboembolism.
Agnelli G; Becattini C; Franco L
Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
[TBL] [Abstract][Full Text] [Related]
16. Multi-analyte analysis of non-vitamin K antagonist oral anticoagulants in human plasma using tandem mass spectrometry.
Blaich C; Müller C; Michels G; Wiesen MH
Clin Chem Lab Med; 2015 Nov; 53(12):1981-90. PubMed ID: 25901716
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
Korostelev M; Bihan K; Ferreol L; Tissot N; Hulot JS; Funck-Brentano C; Zahr N
J Pharm Biomed Anal; 2014 Nov; 100():230-235. PubMed ID: 25173108
[TBL] [Abstract][Full Text] [Related]
18. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of anticoagulants apixaban, dabigatran, edoxaban and rivaroxaban in elderly Japanese patients with atrial fibrillation treated in one general hospital.
Yamazaki-Nishioka M; Kogiku M; Noda M; Endo S; Takekawa M; Kishi H; Ota M; Notsu Y; Shimizu M; Yamazaki H
Xenobiotica; 2019 Sep; 49(9):1001-1006. PubMed ID: 30216091
[TBL] [Abstract][Full Text] [Related]
20. Long-term benefits of preventing venous thromboembolic events.
Cohen AT
Curr Med Res Opin; 2012 Jun; 28(6):877-89. PubMed ID: 22533680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
